• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lumiradx Ltd (NQ: LMDX )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EST, Jan 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Lumiradx Ltd

    LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th
    From LumiraDx Inc
    Via GlobeNewswire
    Stocks Commence 2024 Bullish Rally: LMDX, HNRC, BULT, HALB, SPZI
    Via AB Newswire
    LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Reports Second Quarter 2023 Results
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
    Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional Non-Exclusive Distribution Rights in Germany 
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
    LumiraDx submits a traditional 510(k) Dual Submission for LumiraDx SARS-CoV-2 Ag Ultra with CLIA Waiver for the commercial distribution at point of care of the LumiraDx Platform, including the LumiraDx... 
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Reports First Quarter 2023 Results
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Announces Strategic Refocus and Cost Restructuring Program
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Reports Fourth Quarter and Full Year 2022 Results
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx to Present at Raymond James Institutional Investors Conference
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
    Company receives $14.2M in grants from the Bill & Melinda Gates Foundation to support the TB test’s ongoing development and future launch into developing countries 
    From LumiraDx Inc
    Via GlobeNewswire
    Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers
    LumiraDx shares these and other findings from its second annual U.S. survey “Point of Care Diagnostics: A Clinician's View” 
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
    Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa 
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx Reports Third Quarter 2022 Results
    Progress on Near-Term Growth Opportunities and Cost Savings 
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
    From LumiraDx Inc
    Via GlobeNewswire
    LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA Healthcare Acquisition Corp.
    From CA Healthcare Acquisition Corp.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.